🇺🇸 FDA
Patent

US 11597773

CD6 antibody for treatment of T-cell mediated diseases or disorders

granted A61KA61K2039/505A61P

Quick answer

US patent 11597773 (CD6 antibody for treatment of T-cell mediated diseases or disorders) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61P, A61P37/06